M S Ewer
Overview
Explore the profile of M S Ewer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Azambuja E, Agostinetto E, Procter M, Eiger D, Ponde N, Guillaume S, et al.
ESMO Open
. 2023 Jan;
8(1):100772.
PMID: 36681013
Background: Trastuzumab increases the incidence of cardiac events (CEs) in patients with breast cancer (BC). Dual blockade with pertuzumab (P) and trastuzumab (T) improves BC outcomes and is the standard...
2.
Swain S, Ewer M, Viale G, Delaloge S, Ferrero J, Verrill M, et al.
Ann Oncol
. 2017 Dec;
29(3):646-653.
PMID: 29253081
Background: Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac safety of pertuzumab, trastuzumab, and chemotherapy in the neoadjuvant...
3.
Naing A, Veasey-Rodrigues H, Hong D, Fu S, Falchook G, Wheler J, et al.
Ann Oncol
. 2012 Jun;
23(11):2960-2963.
PMID: 22745218
Background: Cardiac sequelae from oncologic drugs are important in early cancer drug development. Prolongation of the corrected QT interval (QTc) by noncardiac drugs is the most common cause of drug...
4.
Harbeck N, Ewer M, De Laurentiis M, Suter T, Ewer S
Ann Oncol
. 2010 Nov;
22(6):1250-1258.
PMID: 21112929
Adjuvant therapy has improved the survival of women with early breast cancer (BC). Meta-analyses suggest that anthracycline-based regimens reduced the annual BC death rate by ∼40% in women below the...
5.
Verma S, Ewer M
Ann Oncol
. 2010 Nov;
22(5):1011-1018.
PMID: 21097988
The cardiotoxicity of anthracyclines, trastuzumab and other agents is of special importance to adjuvant breast cancer patients whose life expectancy is restored to normal but who may be left with...
6.
Ewer M, Kish S, Martin C, Price K, Feeley T
Cancer
. 2001 Dec;
92(7):1905-12.
PMID: 11745264
Background: Despite advances in cardiopulmonary resuscitation and the education of its providers, survival remains dismal for cancer patients suffering in-hospital cardiac arrest. In an effort to determine if characteristics of...
7.
Berrak S, Ewer M, Jaffe N, Pearson P, RIED H, Zietz H, et al.
Oncol Rep
. 2001 Apr;
8(3):611-4.
PMID: 11295089
We retrospectively reviewed the medical records of 97 children (59 boys and 38 girls) with a median age of 13 +/- 4 years who had been treated with continuous infusion...
8.
9.
Ewer M, Gibbs H, Swafford J, Benjamin R
Semin Oncol
. 1999 Sep;
26(4 Suppl 12):96-101.
PMID: 10482200
Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor family, which produces factors that are considered to be important mediators of cell growth. Overexpression...
10.
Ewer M, Jaffe N, RIED H, Zietz H, Benjamin R
Med Pediatr Oncol
. 1998 Dec;
31(6):512-5.
PMID: 9835904
Background: Doxorubicin cardiotoxicity remains a serious problem in children with malignancy. The present study was undertaken to determine if the administration of consecutive divided daily doses of doxorubicin would significantly...